Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2017 · 10-Q
Revenue$3.47M$3.47M+14.3% vs Q1 2016 Net Income$2.33M$2.33MN/M vs Q1 2016 EPS Diluted$0.55$0.55N/M vs Q1 2016 Gross Profit$1,699,000−8.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow-$4,149,000N/M Margins · derivedGross margin49.0%−12.2 pt vs Q1 2016
Operating margin106.6%+231.8 pt vs Q1 2016
Net margin67.1%+241.6 pt vs Q1 2016
ended Mar 31, 2017 · filed May 12, 2017 · 42 d after period end